![]() |
|
|
|
You are here: Clinical Trials >
Information obtained from ClinicalTrials.gov on June 16, 2008 Link to the current ClinicalTrials.gov record. Condition(s) treated: Cicatrix, Hypertrophic; Keloid Intervention: Silicone gel (Dermatix®) (Drug) Enrollment status: Recruiting Sponsor: University of Schleswig-Holstein
Principal investigator(s) or official(s):
Overall contact:
So far the evaluation of scar treatment was based on subjective criteria. The patient groups were divided into treated versus non-treated. In this study we use patients undergoing ear reconstruction with autologous rib cartilage. The thoracic scar of harvesting the rib cartilage is routinely reopened after 3 month during second stage of reconstruction. Therefore we have a ideal model of clinical, physiological and histological scar evaluation in a homologous patient group. All patients randomly treat one half of the scar with a silicone gel (Dermatix). The other half is untreated as an internal control.
Official title: Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage for Standardised Total Ear Reconstruction Study design: Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study Primary outcome: Beausang's scar scale, skin elasticity (Cutometer®), skin moisture (Corneometer®), skin color (Chromameter®, Mexameter®), histological evaluation (HE, elastica, actin etc.) (Time Frame: 45 minutes) Secondary outcome: allergic reaction compliance (Time Frame: retrospective)
Minimum eligible age: 9 Years. Eligible gender(s): Both. Criteria: Inclusion Criteria:
Stefan Nitsch, MD, Phone: +49 451 500, Ext: 2244, Email: stefan.nitsch@hno.uni.luebeck.de University Hospital Schleswig-Holstein, Luebeck 23564, Germany; Recruiting
Start date: January 2007
Home | About Us | Contact Us | Ask a Question | Resources Copyright © 1999-2008 by Dr. G. Todorov / SmartSkinCare.com Site Disclaimer | Copyright Certification
|
|